Fragment-Based Drug Discovery

Fragment-based drug discovery (FBDD), while still a relatively new approach, has been so successful for identifying ligands for protein targets that it is alreadywidely regarded as representing a sea-change in drug discovery techniques. The strategy involves identifying small (typically ,300Da), low-affinity ligands (‘fragments’) and combining or expanding these to produce larger, higher-affinity ligands. The major advantage of FBDD over more traditional high-throughput screening is that FBDD provides a more rapid and effective means of identifying ligands for a protein target. Because there are fewer possible fragmentsized molecules than leador drug-sized molecules, FBDD samples chemical space far more efficiently than traditional approaches and therefore requires far fewer compounds to be tested to identify suitable hits as starting points for development. Furthermore, fragment-based screening typically provides more ‘developable’ compounds than traditional drug discovery approaches, which optimise amediumto high-affinity hit.Most importantly, fragment methods produce lead candidates with physicochemical properties (described by Lipinski’s ‘rule of five’) that are likely to result in orally bioavailable compounds. FBDD also has the capability of developing inhibitors of protein–protein interactions (PPIs), about which the pharmaceutical industry has had major reservations in the past as drug targets; that skepticism, however, is gradually being eroded as blockers of such interactions progress to the clinic. Indeed, the recent approval of vemurafenib, a B-Raf(V600E) inhibitor developed by Plexxikon for late-stagemelanoma, validates FBDD as an approach to support the development of clinically useful drugs. Moreover, the Practical Fragments blog (http://practicalfragments.blogspot.com.au/2013/01/fragmentsin-clinic-2013-edition.html), hosted by Dan Erlanson, lists 25 fragment-derived compounds in various stages of clinical evaluation, and that number is likely to be an underestimate. The ingredients of a successful fragment-based drug discovery program are a stable biomolecular target that can be produced in milligram quantities, a well-constructed fragment library, one or more biophysical screening methods, and access to medicinal chemistry expertise to develop promising hits. It helps to have a high-resolution structure of the target, determined by either X-ray crystallography of NMR spectroscopy. As all of these are accessible in an academic research environment, and do not require access to sophisticated robotic platforms or dedicated assay development, there is enormous interest in FBDDwithin the academic community in Australasia and elsewhere. As a reflection of this, a two-day workshop ‘Fragment-Based Drug Design Down Under’ was run at the Monash Institute of Pharmaceutical Sciences, Parkville, in November 2012, attracting over 100 participants. This Special Issue of the Australian Journal of Chemistry captures the spirit of this workshop and highlights some of the work being pursued in Australia in this rapidly developing area. Fragment screens can be undertaken with commercially available libraries, although most practitioners prefer to create their own. Issues related to constructing a purpose-built fragment library are described in the articles by Doak et al. and Francis et al. The article by Jonathan Baell and colleagues outlines some of the chemical properties to be wary of in both fragment-based drug discovery and high-throughput screening, as encapsulated in his concept of PAINS. Screening is mostly undertaken using biophysical techniques, as conventional biochemical methods are often not sufficiently sensitive to identify the modest (often mM) affinity of fragments for the target protein. Many such techniques are used to identify fragment hits, each with its own strengths and weaknesses, and it is advisable to employ at least two orthogonal methods to eliminate false positives. Mass spectrometry